Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset

Recent media reports commented about a possible issue of the misuse of antidiabetics related to molecules promoted as a weight-loss treatment in non-obese people. We evaluated here available pharmacovigilance misuse/abuse signals related to <i>semaglutide</i>, a glucagon-like peptide-1 (...

Full description

Bibliographic Details
Main Authors: Stefania Chiappini, Rachel Vickers-Smith, Daniel Harris, G. Duccio Papanti Pelletier, John Martin Corkery, Amira Guirguis, Giovanni Martinotti, Stefano L. Sensi, Fabrizio Schifano
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Pharmaceuticals
Subjects:
semaglutide
drug misuse
drug abuse
pharmacovigilance
image- and performance-enhancing drugs (IPEDs)
glucagon-like peptide-1 (GLP-1) agonists
Online Access:https://www.mdpi.com/1424-8247/16/7/994

Internet

https://www.mdpi.com/1424-8247/16/7/994

Similar Items